



17th
ICML

**International
Conference
on Malignant
Lymphoma**
Lugano

June
13-17
2023

Program Book

The program is subject to changes,
for updates visit www.icml.ch

Organized by In cooperation with



AACR American Association
for Cancer Research®
FINDING CURES TOGETHER™



ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE



CONFERENCE SCHEDULE (updated on June 05)

TUESDAY, JUNE 13

Polivalente room East Campus USI	09:00 – 17:00	CLOSED WORKSHOP Lugano Classification: Looking towards the future Organizing Committee: Bruce D. Cheson, Bethesda, MD, US, Sally Barrington, London, GB, Andrew T. Lister, London, GB, Emanuele Zucca, Bellinzona, CH <i>organized with the support of the American Association for Cancer Research – AACR, the European School of Oncology – ESO and the European Society for Medical Oncology - ESMO</i> (by invitation only)
3 parallel symposia		
Room A	11:30 – 13:00	Kite, A Gilead Company Improving outcomes in R/R DLBCL: Learning from challenging cases Chair: Marie-José Kertsen, Amsterdam, NL
Room B1	11:30 – 13:00	Regeneron Optimizing Treatment Paradigms for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) With the Emerging Class of Bispecific Antibodies
Room B2	11:30 – 13:00	Eli Lilly and Company Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients
4 parallel symposia		
Room A	14:00 – 15:30	Kite, A Gilead Company Evolving survival outcomes with CAR T in 2L DLBCL Chair: Anna Sureda, Barcelona, ES
Room B1	14:00 – 15:30	Novartis Using Real-World Experience to Optimize CAR-T Cell Therapy in Lymphoma Chair: Thorsten Zenz, Zurich, CH

Room B2	14:00 – 15:30	Incyte What to do when CAR Ts are not the most appropriate option in 2L DLBCL. Current treatment options for transplant-ineligible patients Chair: Björn Chapuy, Berlin, DE
Auditorium West Campus USI	14:00 – 15:30	MSD Aggressive B-cell lymphomas, ROR1 modalities and ADCs: Why it Matters Chair: Thomas Kipps, La Jolla, CA, US
Cinema Corso	15:00 – 17:30	LYMPHOMA RADIOTHERAPY WORKSHOP Radiation therapy as an immunogenic cell death mechanism in the environment of immunotherapy and adoptive cell therapy Moderators: Bouthaina S. Dabaja, Houston, TX, US and Joachim Yahalom, New York, NY, US <i>organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG</i> (open to all 17-ICML attendees)
	15:00 – 15:05	Past, present and future (hematology perspective) Stephen Ansell, Rochester, MN, US
	15:05 – 15:25	Experimental basis for the contribution of radiation therapy to CAR-T cell therapy Carl DeSelm, St Louis, MO, US
	15:25 – 15:40	Review of current RT/ CAR-T programs data Brandon Imber, New York, NY, US
	15:40 – 16:00	Break
	16:00 – 16:20	Is there a role for consolidation RT post-CAR-T? Patient selection and technical considerations George Mikhaeel, London, UK
	16:20 – 16:40	Spectrum of CAR-T and future directions Bouthaina S. Dabaja, Houston, TX, US
	16:40 – 16:55	Case presentation and discussion Bouthaina S. Dabaja, Houston, TX, US and Timothy Robinson, New Haven, CT, US
	16:55 – 17:15	Summary and Conclusions Joachim Yahalom, New York, NY, US

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

4 parallel symposia		
Room A	16:30 – 18:00	Bristol Myers Squibb Advances in the Management of B Cell Malignancies: Updates and Future Directions Chair: Jeremy Abramson, Boston, MA, US
Room B1	16:30 – 18:00	Genmab Beyond the Horizon: Perspectives on the Treatment of Later-Line Large B-Cell Lymphoma (LBCL) Chair: Chan Cheah, Perth, AU
Room B2	16:30 – 18:00	Roche T-cell engaging bispecific antibodies in the management of relapsed/refractory follicular lymphoma Chair: Graham Collins, Oxford, GB <i>Satellite symposium abstract available in the Abstract book</i>
Auditorium West Campus USI	16:30 – 18:00	Satellite symposium organized by PeerView, supported by AstraZeneca Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies Chair: Martin Dreyling, Munich, DE
19:00 – 20:30 3 parallel symposia		
Room A	19:00 – 20:30	Roche What does the future hold for DLBCL treatment and prognosis? Chair: Franck Morschhauser, Lille, FR <i>Satellite symposium abstract available in the Abstract book</i>
Room B1	19:00 – 20:30	Sobi Closing the gap: Unmet Needs and Emerging Treatments in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Chair: Georg Lenz, Münster, DE
Room B2	19:00 – 20:30	AbbVie Optimizing Treatment Strategies for Patients with Chronic Lymphocytic Leukemia (CLL): An Expert Discussion Chair: Thorsten Zenz, Zurich, CH

WEDNESDAY, JUNE 14

Article nr.

“MEET THE PROFESSOR” SESSIONS		
5 parallel sessions		
Room A	08:30 – 09:15	Update on Follicular Lymphoma Jonathan W. Friedberg, Rochester, NY, US repeated on Friday, June 16, in Polivalente room
Room B	08:30 – 09:15	Germinal center in the genesis of lymphomas Laura Pasqualucci, New York, NY, US repeated on Friday, June 16, in Auditorium
Cinema Corso	08:30 – 09:15	Are we reaching the maximum cure rate for Hodgkin lymphoma? Peter W.M. Johnson, London, GB repeated on Thursday, June 15, in Room A
Auditorium West Campus USI	08:30 – 09:15	Reappraisal of role of radiation therapy in lymphoma treatment Lena Specht, Copenhagen, DK offered only once
Polivalente room East Campus USI	08:30 – 09:15	Advances in PET and radiomics Sally Barrington, London, GB repeated on Friday, June 16, in Room B
“MEET THE PROFESSOR” SESSIONS		
5 parallel sessions		
Room A	09:30 – 10:15	Peripheral T-cell lymphomas Pier Luigi Zinzani, Bologna, IT repeated on Thursday, June 15, in Room B
Room B	09:30 – 10:15	Marginal zone lymphomas Emanuele Zucca, Bellinzona, CH repeated on Thursday, June 15, in Cinema Corso
Cinema Corso	09:30 – 10:15	Lymphoma in pregnancy Fedro A. Peccatori, Milan, IT offered only once
Auditorium West Campus USI	09:30 – 10:15	Management of Primary and Secondary CNS Lymphoma Kate Cwynarski, London, GB repeated on Thursday, June 15, in Polivalente room

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Polivalente room East Campus USI	09:30 – 10:15	Mantle Cell lymphoma – Update on molecular biology, prognostication and treatment approaches Martin Dreyling, Munich, DE repeated on Friday, June 16, in Room A	EBO4
	10:15 – 10:35	Coffee break	
Marquee	10:00 – 12:00	POSTER SESSION set - up EDUCATIONAL SYMPOSIA 2 parallel sessions	
	10:35 – 12:00	DIFFUSE LARGE B-CELL LYMPHOMAS Chair: Gilles Salles, New York, NY, US	
Room A, broadcast in Cinema Corso	10:35 – 11:00	CAR T-cell Therapy in Large B Cell Lymphoma Gilles Salles, New York, NY, US	EB15
	11:00 – 11:25	The evolving therapy of DLBCL: Bispecific antibodies Martin Hutchings, Copenhagen, DK	EB14
	11:25 – 11:50	Novel Agents in Relapsed/ Refractory Diffuse Large B-cell Lymphoma Ranjana H. Advani, Stanford, CA, US	EB13
	11:50 – 12:00	Discussion	
	12:00 – 13:00	Lunch time and Poster viewing	
Room B, broadcast in Marquee and Polivalente room, East Campus USI	10:35 – 12:00	CHRONIC LYMPHOCYTIC LEUKEMIA Chair: Michael Hallek, Cologne, DE	
	10:35 – 11:00	Functional consequences of inhibition of Bruton's Tyrosine kinase by ibrutinib in chronic lymphocytic leukemia Nicholas Chiorazzi, Manhasset, NY, US	EB16
	11:00 – 11:25	First line therapy of CLL Michael Hallek, Cologne, DE	EB17
	11:25 – 11:50	Therapy of relapsed disease and Richter's Syndrome John F. Seymour, Melbourne, AU	EB18
	11:50 – 12:00	Discussion	

Marquee	12:00 – 18:00	POSTER SESSION Authors will be present in front of their posters from 12:30 to 13:00 for discussion with interested attendees on Thursday, 15 (odd-numbered posters) and Friday, 16 June (even-numbered posters). EPIDEMIOLOGY 157 BIOLOGY 158 - 171 MICROENVIRONMENT 172 - 198 TRANSLATIONAL STUDIES, B-CELL LYMPHOMAS 199 - 216 TRANSLATIONAL STUDIES, PCTL AND cHL 217 - 226 TRANSLATIONAL STUDIES, LIQUID BIOPSY 227 - 241 IMAGING 242 - 251 HODGKIN LYMPHOMA 252 - 267 INDOLENT LYMPHOMAS 268 - 290 EXTRANODAL LYMPHOMAS NON MZL 291 - 303 DLBCL 304 - 337 CLL 338 - 345 MCL 346 - 359 PTCL 360 - 378 PLASMA CELL NEOPLASMS AND AMYLOIDOSIS 379 - 380 CAR-T (CELLULAR THERAPIES) 381 - 402 PRECLINICAL NEW DRUGS 403 - 419 PHASE I-II 420 - 451 PEDIATRIC / YOUNG ADULTS 452 - 455 INFECTIONS 456 - 458	
	13:00 – 13:55	OPENING OF THE CONFERENCE WELCOME AND INTRODUCTORY REMARKS F. Cavalli, Bellinzona, CH HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION PRIZE Introduction to San Salvatore Foundation: Stefano Coduri, Lugano, CH Laudatio: Rolf Stahel, Zurich, CH Lessons Learned from the Genetic Heterogeneity of Lymphoid Malignancies Margaret A. Shipp, Boston, MA, US	001

14:00 – 15:15	PLENARY SESSION Chairs: Franco Cavalli, Bellinzona, CH and Catherine Thieblemont, Paris, FR	
14:00 – 14:15	Frontline intensified ABVD demonstrates superior efficacy than PET-adapted ABVD in advanced Hodgkin Lymphoma: the FIL-Rouge Phase 3 Trial by the Fondazione Italiana Linfomi Antonio Pinto, Naples, IT	004
14:15 – 14:30	Nivolumab(N)-AVD Improves Progression-Free Survival Compared to Brentuximab Vedotin (BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL): Results of SWOG S1826 Alex F. Herrera, Duarte, CA, US	005
14:30 – 14:45	Discussant Peter Borchmann, Cologne, DE	
14:45 – 15:00	Fourth generation huCART19-IL18 produces durable responses in lymphoma patients previously relapsed/refractory to anti-CD19 CAR T-cell therapy Jakub Svoboda, Philadelphia, PA, US	006
15:00 – 15:15	Discussant Gilles Salles, New York, NY, US	
Marquee	15:15 – 15:45 Coffe break	
Room A, broadcast in all rooms	15:45 – 16:45 AACR – ICML JOINT SESSION Technology that will change lymphoma understanding and care Chairs: Francesco Bertoni, Bellinzona, CH and Margaret Foti, Philadelphia, PA, US	
15:45 – 16:05	Single cell omics in the study of B cell lymphoma Katia Basso, New York, NY, US	007
16:05 – 16:25	Circulating tumor DNA (liquid biopsy) Davide Rossi, Bellinzona, CH	008
16:25 – 16:45	Organoids Arianna Baggiolini, Bellinzona, CH	009

“FOCUS ON...” SESSIONS

5 parallel sessions

Room A	17:00 – 18:00	Mantle Cell Lymphoma Chairs: Martin Dreyling, Munich, DE and John P. Leonard, New York, NY, US	
	17:00 – 17:10	Five-year update of the first-line IMCL-2015 GELTAMO study. Prolonged molecular and clinical responses were observed after MRD-driven ibrutinib discontinuation Eva Giné, Barcelona, ES	098
	17:10 – 17:20	Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma – a phase II clinical trial Preetesh Jain, Houston, TX, US	099
	17:20 – 17:30	Very Long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study. Clémentine Sarkozy, Saint Cloud, FR	100
	17:30 – 17:40	Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma – phase-II WINDOW-2 trial Michael L. Wang, Houston, TX, US	101
	17:40 – 17:50	Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: updated results, subgroup analysis from BRUIN with >3 years follow-up from start of enrollment Chan Y. Cheah, Perth, AU	102
	17:50 – 18:00	Outcomes of autologous transplant, allogeneic transplant, and CAR T cell therapy in TP53 altered mantle cell lymphoma: a multi-institution retrospective analysis Marcus Messmer, Philadelphia, PA, US	103

Room B, broadcast in Marquee	17:00 – 18:00	Hodgkin Lymphoma Chairs: Ranjana H. Advani, Stanford, CA, US and Peter Borchmann, Cologne, DE	
	17:00 – 17:10	Correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from GHSG trials Paul J. Bröckelmann, Cologne, DE	104
	17:10 – 17:20	Early FDG-PET adapted treatment of limited stage Hodgkin lymphoma (HL): 10y long term follow-up analysis of the randomized Intergroup EORTC/LYSA/FIL H10 trial Massimo Federico, Modena, IT	105
	17:20 – 17:30	Pembrolizumab as first therapy for Hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival Michael J. Dickinson, Melbourne, AU	106
	17:30 – 17:40	Phase 2 trial of Nivolumab plus Adriamycin, Vinblastine, Dacarbazine (N-AVD) as Frontline Therapy in Older Adults with Hodgkin Lymphoma Pallawi Torka, New York, NY, US	107
	17:40 – 17:50	Avelumab monotherapy followed by a PET adapted chemotherapy approach in the first line treatment of classical Hodgkin Lymphoma: Initial results from the AVeNuE window study Graham P. Collins, Oxford, GB	108
	17:50 – 18:00	Favezelimab plus pembrolizumab in anti-PD-1-refractory classical Hodgkin lymphoma (cHL): Estimating the relative efficacy of favezelimab Philippe Armand, Boston, MA, US	109
	Cinema Corso	17:00 – 18:00	Ongoing trials Chairs: John Kuruvilla, Toronto, ON, CA and Grzegorz S. Nowakowski, Rochester, NJ, US
	17:00 – 17:10	SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial. Anastasios Stathis, Bellinzona, CH	OT1
	17:10 – 17:20	REMoDL-A: A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma (DLBCL) with Acalabrutinib Vivek S. Radhakrishnan, Southampton, GB	OT2
	17:20 – 17:30	Brentuximab Vedotin-Nivolumab alone and then with Rituximab-Cyclophosphamide-Doxorubicin-Prednisone as Frontline Therapy of Primary Mediastinal Large B-cell Lymphoma Raphael E. Steiner, Houston, TX, US	OT3
	17:30 – 17:40	MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma Laurie H. Sehn, Vancouver, BC, CA	OT4
	17:40 – 17:50	SUNMO: Phase III trial of mosunetuzumab plus polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in relapsed/refractory aggressive non-Hodgkin lymphoma Astrid Pavlovsky, Buenos Aires, AR	OT5
	17:50 – 18:00	ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucef vs Standard of Care as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma Jason R. Westin, Houston, TX, US	OT6
Auditorium West Campus USI	17:00 – 18:00	Liquid Biopsy and Minimal Residual Disease Chairs: Christiane Pott, Kiel, DE and Davide Rossi, Bellinzona, CH	
	17:00	Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels Riccardo Moia, Novara, IT	110

17:10	Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study Alex F. Herrera, Duarte, CA, US	111	
17:20	MRD-Negativity After Frontline DLBCL Therapy: Pooled Analysis of 6 Clinical Trials Mark Roschewski, Bethesda, MD, US	112	
17:30	Early ctDNA clearance after CAR T-cell infusion predicts outcome in patients with Large B-cell lymphoma: results from ALYCANTE, a phase 2 LYSA study Marie-Hélène Delfau-Larue, Creteil, FR	113	
17:40	Cell-free DNA kinetics decipher potential mechanisms of action of Ibrutinib combination therapy in mantle cell lymphoma (MCL) Mouhamad Khouja, Kiel, DE	114	
17:50	Combined use of minimal residual disease monitoring and FDG-PET for outcome prediction in follicular lymphoma: results from the Fondazione Italiana Linfomi (FIL) FOLL12 trial Simone Ferrero, Turin, IT	115	
Polivalente room East Campus USI	17:00 – 18:00	Mechanisms of treatment resistance Chairs: Vincent Ribrag, Villejuif, FR and Patrizia Mondello, Rochester, MN, US	
	17:00 – 17:10	Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN study Krish Patel, Seattle, WA, US	116
	17:10 – 17:20	Single-cell RNA-Seq of classic hairy cell leukemia reveals disease drivers linked to intrinsic treatment resistance and identifies DUSP1 as potential new therapeutic target Jan-Paul Bohn, Innsbruck, AT	117

17:20 – 17:30	IL16 production is a mechanism of resistance to BTK inhibitors and to R-CHOP Alberto Arribas, Bellinzona, CH	118
17:30 – 17:40	Enhancer RNAs (eRNAs) play a role in the response to small molecules and in the development of acquired resistance in marginal zone lymphoma (MZL). Sara Napoli, Bellinzona, CH	119
17:40 – 17:50	Harnessing BTKi therapy by CDK4/6i control of T cell surveillance Selina Chen-Kiang, New York, NY, US	120
17:50 – 18:00	Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma Preetesh Jain, Houston, TX, US	121

3 parallel symposia

Room A	19:00 – 20:30	AbbVie Navigating the Rapidly Changing Treatment Landscape in DLBCL Chair: Georg Lenz, Münster, DE
Room B	19:00 – 20:30	Takeda The future of therapy for CD30+ lymphomas: addressing challenges and driving progress Chair: Anna Sureda, Barcelona, ES
Auditorium West Campus USI	19:00 – 20:30	BeiGene Targeting BTK across B-Cell Malignancies – Selecting the right treatment for patients with lymphoma or CLL Chair: Stephen Stilgenbauer, Ulm, DE

THURSDAY, JUNE 15

“MEET THE PROFESSOR” SESSIONS

5 parallel sessions

Room A	08:15 – 09:00	Are we reaching the maximum cure rate for Hodgkin lymphoma? Peter W.M. Johnson, London, GB repetition	EB07
---------------	---------------	---	------

Room B	08:15 – 09:00	Peripheral T-cell lymphomas Pier Luigi Zinzani, Bologna, IT repetition	EB11
Cinema Corso	08:15 – 09:00	Marginal zone lymphomas Emanuele Zucca, Bellinzona, CH repetition	EB12
Auditorium West Campus USI	08:15 – 09:00	Post-Transplant Lymphoproliferative Disease (PTLD) in Children, Adolescents, and Young Adults Thomas Gross, Aurora, CO, US offered only once	EB06
Polivalente room East Campus USI	08:15 – 09:00	Management of Primary and Secondary CNS Lymphoma Kate Cwynarski, London, GB repetition	EB03
Marquee	09:00 – 18:00	POSTER SESSION “CLINICAL CASES DISCUSSION” SESSIONS 3 parallel sessions	
Room A	09:15 – 10:30	HODGKIN AND T-CELL LYMPHOMAS Chair: Andrew T. Lister, London, UK Presenter: Alden Moccia, Bellinzona, CH Discussants: Richard Hoppe, Stanford, CA, US, Andrew T. Lister, London, UK and Astrid Pavlovsky, Buenos Aires, AR	
Cinema Corso	09:15 – 10:30	INDOLENT NHLs AND CLL Chair: Jonathan Friedberg, Rochester, NY, US Presenter: Adalgisa Condoluci, Bellinzona, CH Discussants: Jonathan Friedberg, Rochester, NY, US, Mary Gospodarowicz, Toronto, ON, CA and Michael Hallek, Cologne, DE	
Auditorium West Campus USI	09:15 – 10:30	PEDIATRIC LYMPHOMAS Chair: Wilhelm Wössmann, Hamburg, DE Presenter: Francesco Ceppi, Lausanne, CH Discussant: Thomas Gross, Aurora, CO, US	
Room B, broadcast in Marquee	09:15 – 10:30	SESSION 1 - DISSECTING LYMPHOMAS AT THE SINGLE CELL LEVEL Chair: Elias Campo, Barcelona, ES and Leticia Quintanilla de Fend, Tübingen, DE	

	09:15 – 09:35	The tumor microenvironment of Hodgkin lymphoma at single cell resolution Christian Steidl, Vancouver, B.D., CA	010
	09:35 – 09:55	Trajectories of lymphomagenesis Bertrand Nadel, Marseille, FR	011
	09:55 – 10:15	Subclonal heterogeneity driving progression and transformation in chronic lymphocytic leukemia Elias Campo, Barcelona, ES	012
	10:15 – 10:30	Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma Ivana Spasevska, Oslo, NO	013
Polivalente room East Campus USI	09:15 – 10:30	SESSION 2 - LYMPHOMAS AFFECTING THE CNS Chairs: Kate Cwynarski, London, GB and Andrés J. Ferreri, Milan, IT 5 parallel sessions	
	09:15 – 09:30	Identification of Genomic Biomarkers of Disease Progression and Survival in Newly-Diagnosed Primary CNS Lymphoma James Rubenstein, San Francisco, CA, US	014
	09:30 – 09:45	Consolidative HCT-ASCT is superior to non-myeloablative chemo-immunotherapy in newly-diagnosed PCNSL - Updated results of the randomized phase III MATRix/IELSG43 trial Gerard Illerhaus, Stuttgart, DE	015
	09:45 – 10:00	CAR-T cells radically modify the management of relapsed/refractory primary cerebral lymphomas. Real life results of the French LOC network Sylvain Choquet, Paris, FR	016
	10:00 – 10:15	Phase 2 study of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDi-R) for secondary CNS lymphoma Mark Roschewski, Bethesda, MD, US	017

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

	10:15 – 10:30	Five-year results of a phase 2 study of CNS-oriented therapy with R-CHOP for untreated intravascular large B-cell lymphoma: Final analysis of the PRIMEUR-IVL study Kazuyuki Shimada, Nagoya, JP	018
Marquee	10:30 – 11:00	Coffee break	
Room A, broadcast in all rooms	11:00 – 12:00	SESSION 3 - TREATMENT OF AGGRESSIVE LYMPHOMAS Chair: Franck Morschhauser, Lille, FR and Laurie H. Sehn, Vancouver, BC, CA	
	11:00 – 11:15	A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy. Andrew J. Davies, Southampton, GB	019
	11:15 – 11:30	R-CODOX-M/R-IVAC versus DA-EPOCH-R in Patients with newly diagnosed high-risk Burkitt lymphoma: Final results of a multi-center randomized HOVON/SAKK trial. Martine Chamuleau, Amsterdam, NL	020
	11:30 – 11:45	Biomarker-driven treatment strategy in high-risk large B-cell lymphoma (NLG-LBC-06 phase II trial): Impact of ctDNA and TP53 aberrations on clinical outcome Sirpa Leppa, Helsinki, FI	021
	11:45 – 12:00	Primary overall survival analysis of the Phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard of care in relapsed/refractory large B cell lymphoma Jason R. Westin, Houston, TX, US	022
Marquee	12:00 – 13:00	Lunch time and Poster viewing	

Room A, broadcast in all rooms	13:00 – 13:45	GIANNI BONADONNA MEMORIAL LECTURE Supported by the European School of Oncology – ESO Laudatio : Riccardo Dalla-Favera, New York, NY, US Elucidating the enigmatic pathobiology of Hodgkin lymphoma Ralf Küppers, Essen, DE	002
Room A, broadcast in room B, Marquee, Cinema Corso and Polivalente room, East Campus USI	13:45 – 15:15	SESSION 4 - CLL AND RICHTER SYNDROME Chairs: Michael J. Hallek, Cologne, DE and Thorsten Zenz, Zurich, CH	
	13:45 – 14:00	FoxO1-Rictor axis induces Akt phosphorylation during CLL cell adaptation to BCR inhibitors: implications for combinatorial therapy Laura Ondrisova, Brno, CZ	023
	14:00 – 14:15	Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): Final results of the CLL12 trial Petra Langerbeins, Cologne, DE	024
	14:15 – 14:30	Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study Othman Al-Sawaf, Cologne, DE	025
	14:30 – 14:45	Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004 Tanya Siddiqi, Duarte, CA, US	026
	14:45 – 15:00	Efficacy and safety of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter Syndrome Anna M. Frustaci, Milan, IT	027
	15:00 – 15:15	Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter's transformation Carmelo Carlo-Stella, Milan, IT	028

Auditorium West Campus USI	13:45 – 16:45	SESSION 5 - PEDIATRIC LYMPHOMAS Chair: Francesco Ceppi, Lausanne, CH	
	13:45 – 14:10	Primary mediastinal B cell lymphoma in children, adolescents and young adults Lisa Giulino Roth, New York, NY, US	029
	14:10 – 14:35	Minimal disseminated and residual disease in pediatric NHL Wilhelm Wössmann, Hamburg, DE	030
	14:35 – 14:50	Phase 2 KEYNOTE-667: Pembrolizumab in children and young adults with classical Hodgkin lymphoma (cHL) with slow early response to front-line chemotherapy Luciana Vinti, Rome, IT	031
	14:50 – 15:05	Analysis treatment outcome of 46 refractory/relapsed pediatric mature B cell lymphoma patients-multi- center experience from China Yonghong Zhang, Beijing, CN	032
	15:05 – 15:20	Allogeneic hematopoietic stem cell transplantation with reduced-toxicity conditioning for pediatric relapsed or refractory ALK-positive anaplastic large cell lymphoma Fabian Knörr, Hamburg, DE	033
	15:20 – 15:35	Patterns of presentation and outcomes in Stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial Dana Casey, Chapel Hill, NC, US	034
	15:35 – 15:45	Break	
	15:45 – 15:57	Landscape of driver mutations and their clinical impacts in Chinese pediatric patients with mature B-cell non-Hodgkin's lymphoma and T-cell lymphoblastic lymphoma Qinlong Zheng, Beijing, CN	035
	15:57 – 16:09	ALK-positive anaplastic large cell lymphoma with variant ALK-fusion partner: a population-based analyses of the NHL-BFM study group Christine Damm-Welk, Hamburg, DE	036

	16:09 – 16:21	Lung staging in pediatric Hodgkin Lymphoma: Staging Evaluation & Response Criteria Harmonization for Childhood, Adolescent & Young Adult HL (SEARCH for CAYAH) consensus (432) Jennifer Seelisch, London, CA	037
	16:21 – 16:33	Quality of Life in Pediatric High-Risk Hodgkin Lymphoma Treated with Brentuximab-Based Intensive Chemotherapy—Comparison to Historical Treatment Cohort and Healthy Peers Angela M. Feraco, Boston, MA, US	038
	16:33 – 16:45	Quantitative whole-body MRI for predicting treatment outcome in pediatric patients with aggressive non-Hodgkin lymphoma undergoing chimeric antigen receptor T cell therapy Yu Xia Li, Weihui, CN	039
Marquee	15:15 – 15:30	Coffee break	
Room A, broadcast in Cinema Corso	15:30 – 16:45	SESSION 6 - PERIPHERAL T-CELL LYMPHOMAS Chairs : Julie Vose, Omaha, NE, US and Pier Luigi Zinzani, Bologna, IT	
	15:30 – 15:45	The genetic subtypes and the tumor microenvironment signatures are associated with distinct outcomes in peripheral T-cell lymphoma Yasuhito Suehara, Tsukuba, JP	040
	15:45 – 16:00	Romidepsin plus CHOP versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: final analysis of the Ro-CHOP trial Vincent Camus, Rouen, FR	041
	16:00 – 16:15	Targeted agents combined with CHOP compared with CHOP as the first-line therapy for peripheral T-cell lymphoma: preliminary results from a phase 2 GUIDANCE-03 Trial Weili Zhao, Shanghai, CN	042
	16:15 – 16:30	Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Primary Analysis of the Multinational Pivotal Study Results (JACKPOT8) Won Seog Kim, Seoul, KR	043

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

	16:30 – 16:45	First in human study of AUTO4, a TRBC1-tragetting CART T cell therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-cell Lymphoma Kate Cwynarski, London, GB	044
Room B, broadcast in Marquee and Polivalente room, East Campus USI	15:30 – 16:45	SESSION 7 - NEW CAR-T CELL APPROACHES Chairs: Elise A. Chong, Philadelphia, PA, US and Anna Sureda, Barcelona, ES	
	15:30 – 15:45	Phase 2 Study of Anbal-cel, Novel Anti-CD19 CAR-T therapy with Dual Silencing of PD-1 and TIGIT in Relapsed or Refractory Large B Cell Lymphoma - Interim Analysis Result Won Seog Kim, Seoul, KR	045
	15:45 – 16:00	Point-of-care anti-BCMA CAR T-cell therapy induces encouraging response rates in high-risk relapsed/refractory multiple myeloma Hila Magen, Tel Hashomer, IL	046
	16:00 – 16:15	Off-the-shelf CD30.CAR-modified Epstein-Barr Virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL) Carlos A. Ramos, Houston, TX, US	047
	16:15 – 16:30	Durables responses with anti-CD19 allogeneic CAR T ALLO-501/501A in phase 1 trials of relapsed/refractory large B-cell lymphoma (r/r LBCL) Frederick L. Locke, Tampa, FL, US	048
	16:30 – 16:45	High efficacy and favorable safety of 3rd generation CD20 CAR-T (MB-106) for outpatient treatment of follicular lymphoma (FL) – results of a single-institution trial Mazyar Shadman, Seattle, WA, US	049

“FOCUS ON...” SESSIONS

5 parallel sessions

Room A	17:00 – 18:00	T-Cell Lymphomas Chairs: Stefano Luminari, Reggio Emilia, IT and Won Seog Kim, Seoul, KR
---------------	---------------	--

	17:00 – 17:10	Lack of SMARCB1 expression characterizes a subset of peripheral T-cell lymphomas enriched in children and young adults Anja Fischer, Ulm, DE	122
	17:10 – 17:20	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas Edith Julia, Lyon, FR	123
	17:20 – 17:30	BRCA1/2 mutations impact on the development of breast implant-associated lymphoma (BIA-ALCL) in women with breast cancer reconstructed with textured breast implants. Paola Ghione, New York, NY, US	124
	17:30 – 17:40	A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma. Atae Utsunomiya, Kagoshima, JP	125
	17:40 – 17:50	AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the Phase 2 REDIRECT study Won Seog Kim, Seoul, KR	126
	17:50 – 18:00	Lacutamab in patients with advanced mycosis fungoides (MF): efficacy results according to updated lymph node (LN) classification in the TELLOMAK study Pierluigi Porcu, Philadelphia, PA, US	127

Room B, broadcast in Marquee	17:00 – 18:00	CAR-T Cell Chairs: Tanya Siddiqi, Duarte, CA, US and Jason R. Westin, Houston, TX, US
---	---------------	---

	17:00 – 17:10	Proteomic profiling identifies granzyme B inhibitor Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in nodal B-cell lymphoma Berit J. Brinkmann, Heidelberg, DE	128
--	---------------	---	-----

17:10 – 17:20	CART-SIE real life study: primary mediastinal B-cell lymphoma (PMBCL) have a superior outcome compared to large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel Annalisa Chiappella, Milan, IT	129
17:20 – 17:30	Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T-cell therapy for aggressive B-cell lymphoma Beatriz Wills, New York, NY, US	130
17:30 – 17:40	Bendamustine lymphodepletion triggers reduced inflammatory cytokines and decreased toxicities after both 4-1BB- and CD28-costimulated CART19 for non-Hodgkin lymphoma Guido Ghilardi, Philadelphia, PA, US	131
17:40 – 17:50	Prognostic scoring systems for severe CRS and ICANS after autologous anti-CD19 CAR T cells in large B-cell lymphoma: a DESCAR-T registry study form the LYSA Pierre Sesques, Pierre Benite, FR	132
17:50 – 18:00	Severe hematological toxicity following CD19 CAR-T for relapsed/refractory LBCL is associated with suppressive immune dysregulation and limited CAR-T expansion Kai Rejeski, Munich, DE	133
Cinema Corso 17:00 – 18:00	Large B-Cell and Double Hit Lymphomas Chairs: Andrew J. Davies, Southampton, GB and Brad Kahl, Saint Louis, MO, US	
17:00 – 17:10	MYC/BCL6 double hit lymphoma negative for t(3;8) BCL6::MYC fusion is associated with inferior survival, in contrast with t(3;8) positive pseudo-double hit lymphoma Bernard D. Maybury, Birmingham, GB	134

17:10 – 17:20	High complete metabolic response rates with epcoritamab + R-CHOP in previously untreated (1L) high-risk DLBCL, including double-hit/triple-hit: EPCORE NHL-2 update Lorenzo Falchi, New York, NY, US	135
17:20 – 17:30	waveLINE-004: open-label, phase 2 study of zilovetamab vedotin (MK-2140) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Alexander Fosså, Oslo, NO	136
17:30 – 17:40	Long-term responses with loncastuximab tesirine: updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large b-cell lymphoma Paolo F. Caimi, Cleveland, OH, US	137
17:40 – 17:50	Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line therapy in large B-cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response Loretta J. Nastoupil, Houston, TX, US	138
17:50 – 18:00	Comparative accuracy of alternative early measures of residual disease after CAR19 therapy of relapsed/refractory LBCL Brian J. Sworder, Palo Alto, CA, US	139
Auditorium West Campus USI	17:00 – 18:00 Radiotherapy Chairs: Bouthaina S. Dabaja, Houston, TX and Lena Specht, Copenhagen, DK	
17:00 – 17:10	Rituximab-Containing Combined Modality Therapy in Limited Stage Follicular Lymphoma: Mature follow up and derivation of a novel prognostic score from the TROG99.03 Trial Michael MacManus, Brisbane, AU	140
17:10 – 17:20	Radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR-T – The UK experience Andrea Kuhn, London, GB	141

	17:20 – 17:30	High rate of metabolic complete response after low dose radiotherapy and Obinutuzumab in early stage follicular lymphoma: Initial results of the GAZAI study (GLA 2018-3) Klaus Herfarth, Heidelberg, DE	142
	17:30 – 17:40	Very low dose Radiation therapy for Indolent lymphoma: Comparing “Big Boom” (4Gy x 1) versus “Boom Boom” (2Gy x 2) Joachim Yahalom, New York, NY, US	143
	17:40 – 17:50	Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure Chirayu Patel, Boston, MA, US	144
	17:50 – 18:00	Bone marrow volume irradiated and risk of cytopenias in aggressive B-cell lymphoma patients bridged with radiation therapy for CART cell therapy Bouthaina S. Dabaja, Houston, TX	145
Polivalente room East Campus USI	17:00 – 18:00	Lymphoma microenvironment Chairs: Nicholas Chiorazzi, Manhasset, NY, US and Laurence L. de Leval, Lausanne, CH	
	17:00 – 17:10	Immune contexture analysis in POLARIX suggests response to Pola-R-CHP treatment reduces tumor microenvironment dependency Franck Morschhauser, Lille, FR	146
	17:10 – 17:20	Spatially-resolved transcriptomics define clinically relevant subsets of macrophages in diffuse large B-cell lymphoma Anand D. Jeyasekharan, Singapore, SG	147
	17:20 – 17:30	Coordinated changes in the tumor microenvironment (TME) are associated with increased risk of therapeutic failure in newly diagnosed diffuse large B-cell lymphoma (DLBCL) José C. Villasboas, Rochester, MN, US	148

	17:30 – 17:40	EZH2 inhibition enhances CAR T antitumor effect by inducing lymphoma immunogenicity and enhancing T cell function Wendy Béguelin, New York, NY, US	149
	17:40 – 17:50	Single cell analysis reveals immune dysfunction in large B cell Lymphoma (LBCL) pts with hypomagnesemia receiving Axi-cel: results from ZUMA-1 trial and Mayo Clinic cohort Patrizia Mondello, Rochester, MN, US	150
	17:50 – 18:00	Follicular lymphoma patient-derived organoids for bispecific T-cell engager immunotherapy Joseph G. Schroers-Martin, Stanford, CA, US	151

3 parallel symposia

Room A	19:00 – 20:30	Kite, A Gilead Company How do we improve outcomes for underserved populations with B-cell malignancies? Chair: Davide Rossi, Bellinzona, CH
Room B	19:00 – 20:30	Janssen Optimizing treatment for patients with CLL and MCL now and in the future Chair: John Gribben, London, GB
Auditorium West Campus USI	19:00 – 20:30	Follicular Lymphoma Foundation What will it take to cure Follicular Lymphoma? Chair: Mitchell Smith, CMO at the FLF, London, GB

FRIDAY, JUNE 16

“MEET THE PROFESSOR” SESSION

5 parallel sessions

Room A	08:15 – 09:00	Mantle Cell lymphoma – Update on molecular biology, prognostication and treatment approaches Martin Dreyling, Munich, DE repetition	EB04
Room B	08:15 – 09:00	Advances in PET and radiomics Sally Barrington, London, GB repetition	EB01

Cinema Corso	08:15 – 09:00	Cutaneous T-cell lymphomas – focus on some problems and some solutions Helmut Beltraminelli, Locarno, CH offered only once	EB02
Auditorium West Campus USI	08:15 – 09:00	Germinal center in the genesis of lymphomas Laura Pasqualucci, New York, NY, US repetition	EB08
Polivalente room East Campus USI	08:15 – 09:00	Update on Follicular Lymphoma Jonathan W. Friedberg, Rochester, NY, US repetition	EB05
Marquee	09:00 – 18:00	POSTER SESSION	
Auditorium West Campus USI	09:00 – 12:00	LYMPHOMA RADIOTHERAPY WORKSHOP Opportunities in Lymphoma Radiation Therapy Today: Lower Doses, Fewer Fractions, and Real World “Big Data” Analyses using Machine Learning and Artificial Intelligence Moderators: Lena Specht, Copenhagen, DK and Mary Gospodarowicz, Toronto, ON, CA <i>organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG</i> (open to all 17-ICML attendees)	
	09:00 – 09:30	Background for lower and ultra-low radiation doses for lymphoma Andrea Ng, Boston, Massachusetts, US	
	09:30 – 09:50	Clinical Experience with ultra-low dose regimens in indolent lymphomas – lessons from the COVID experience Joanna Yang, St. Louis, MO, US	
	09:50 – 10:20	Background for fewer but larger fractions (hypofractionation) Umberto Ricardi, Turin, IT	
	10:20 – 10:40	Clinical experience with hypofractionation – lessons from the COVID experience Joanna Yang, St. Louis, MO, US	
	10:40 – 12:00	Real world “Big Data” analyses to discover what really works Lena Specht, Copenhagen, DK	

“CLINICAL CASES DISCUSSION” SESSIONS

2 parallel sessions

Room A	09:15 – 10:30	AGGRESSIVE NHLs Chair: John P. Leonard, New York, NY, US Presenter: Maria Cristina Piroso, Bellinzona, CH Discussants: Brad Kahl, Saint Louis, MO, US and John P. Leonard, New York, NY, US	
Cinema Corso	09:15 – 10:30	DIFFICULT PATHOLOGICAL CASES Chair: Luca Mazzucchelli, Locarno, CH Presenters: Luca Mazzucchelli, Locarno, CH and Emanuele Zucca, Bellinzona, CH Discussants: Stephan Dirnhofer, Basel, CH and Leticia Quintanilla de Fend, Tuebingen, DE	
Room B, broadcast in Marquee	09:15 – 10:30	SESSION 8 - EPIGENETIC MECHANISMS AND TARGETED THERAPIES IN B- AND T-CELL LYMPHOMAS Chairs: Ari M. Melnick, New York, NY, US and Margaret A. Shipp, Boston, MA, US	
	09:15 – 09:35	Epigenetic basis and therapy of DLBCL Ari M. Melnick, New York, NY, US	050
	09:35 – 09:55	Epigenetic regulation of immune microenvironment interactions in lymphoma Michael R. Green, Houston, TX, US	051
	09:55 – 10:55	Epigenetic basis and therapy of follicular helper T-cell lymphomas François Lemonnier, Créteil, FR	052
	10:15 – 10:30	Super-enhancer hypermutation in DLBCL: role of alterations in the glucocorticoid receptor pathway Elodie Bal, New York, NY, US	053
Polivalente room East Campus USI	09:15 – 10:30	SESSION 9 - LYMPHOMA IMAGING Chairs: Sally F. Barrington, London, GB and Bruce D. Cheson, Bethesda, MD, US	
	09:15 – 09:30	Baseline PET Radiomics Outperforms Clinical Risk Scores in Predicting Primary Mediastinal B-Cell Lymphoma Outcome: Insights from the IELSG37 Study Luca Ceriani, Bellinzona, CH	054

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

	09:30 – 09:45	Risk stratification of DLBCL with MVED2 score using integrative host adipose density and metabolic tumor characteristics compared to other indexes Catherine Thieblemont, Paris, FR	055
	09:45 – 10:00	Baseline SUV and early response, but not MTV, are associated with outcome in relapsed/refractory Hodgkin lymphoma patients treated with nivolumab in the CHECKMATE 205 trial Sally F. Barrington, London, GB	056
	10:00 – 10:15	Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome Brandon S. Imber, New York, NY, US	057
	10:15 – 10:30	Radiomics reflecting both tumor and host features improves outcome prediction in follicular lymphoma Louis Rebaud, Paris, FR	058
Marquee	10:30 – 11:00	Coffee break	
Room A, broadcast in Room B, Marquee, Cinema Corso and Polivalente room, East Campus USI	11:00 – 12:00	SESSION 10 - HODGKIN LYMPHOMA Chairs: Andrew T. Lister, London, GB and Astrid Pavlovsky, Buenos Aires, AR	
	11:00 – 11:15	Genetically Distinct Pathogenesis of Epstein-Barr Virus (EBV)-positive Versus EBV-negative Classical Hodgkin (cHL) Lymphoma Enrico Tiacci, Perugia, IT	059
	11:15 – 11:30	Distinct Hodgkin lymphoma subtypes identified by noninvasive genomic profiling Stefan K. Alig, Stanford, CA, US	060
	11:30 – 11:45	Dual targeting of Hodgkin's Lymphoma by anti-CD30 CAR-T cells co-transduced with an anti-PDL1 costimulatory receptor to overcome the immunosuppressive microenvironment Brunangelo Falini, Perugia, IT	061

	11:45 – 12:00	The prognostic impact of clinical factors and immunoarchitectural patterns for nodular lymphocyte-predominant Hodgkin lymphoma: an international study by GLOW Michael S. Binkley, Stanford, CA, US	062
Marquee	12:00 – 13:00	Lunch time and Poster viewing	
Room A, broadcast in all rooms	13:00 – 13:45	JOHN ULTMANN MEMORIAL LECTURE Supported by the American Association for Cancer Research – AACR Laudatio: Jonathan W. Friedberg, Rochester, NY, US 25 years of antibody treatments for lymphoma Peter W.M. Johnson, Southampton, GB	003
Room A, broadcast in Cinema Corso	13:45 – 15:00	SESSION 11 - MARGINAL ZONE LYMPHOMA Chairs: Izidore S. Lossos, Miami, FL, US and Grzegorz S. Nowakowski, Rochester, NJ, US	
	13:45 – 14:00	Marginal Zone Lymphoma International Prognostic Index (MZL-IPI): a prognostic score for the entire spectrum of marginal zone lymphomas. A FIL and SPORE-MER study Stefano Luminari, Reggio Emilia, IT	063
	14:00 – 14:15	Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location Juan P. Alderuccio, Miami, FL, US	064
	14:15 – 14:30	Rituximab and Ibrutinib Combination Is Safe and Effective in Untreated Splenic and Nodal Marginal Zone Lymphomas: Planned Subset Analysis of the IELSG47/MALIBU Phase II Study Catherine Thieblemont, Paris, FR	065
	14:30 – 14:45	The IELSG39 Trial: Efficacy of First-Line Chlamydia psittaci Eradication with a Six-Month Regimen of Doxycycline in Patients with Stage-I MALT Lymphoma of the Ocular Adnexae Andrés J. M. Ferreri, Milan, IT	066

	14:45 – 15:00	Immunotherapy alone versus chemoimmunotherapy as first-line treatment of marginal zone lymphoma (MZL): a real-world analysis Adam J. Olszewski, Providence, RI, US	067
Room B, broadcast in Marquee	13:45 – 15:00	SESSION 12 - LYMPHOMA BIOLOGY Chairs: Riccardo Dalla-Favera, New York, NY, US and Gianluca Gaidano, Novara, IT	
	13:45 – 14:00	BTG2 super-enhancer mutations disrupt TFAP4 binding and dysregulate BTG2 expression in Diffuse Large B-cell Lymphoma Elodie Bal, New York, NY, US	068
	14:00 – 14:15	Clonal architecture of relapsed or refractory follicular helper T-cell lymphoma: an ancillary study of the ORACLE trial, a LYSA study François Lemonnier, Creteil, FR	069
	14:15 – 14:30	Molecular characterization contributes to diagnosis and predicts outcome in primary mediastinal large B-cell lymphomas: a LYSA study Vincent Camus, Rouen, FR	070
	14:30 – 14:45	Gene expression profiling of t(14;18)-negative CD23+ follicle center lymphoma demonstrates activation of the IL4/JAK/STAT6 pathway and a role in its pathogenesis Tim-Colin Schade, Tuebingen, DE	071
	14:45 – 15:00	Immunoglobulin class dictates transformation trajectory and BCR status of MYC/BCL2 double-hit lymphoma: biology and clinical implications Stefano Casola, Milan, IT	072
Auditorium West Campus USI	14:30 – 16:30	IBSA FOUNDATION SPECIAL FORUM Personalized therapy in oncology Moderator: Andrea Alimonti, Bellinzona, CH <i>Organized by IBSA Foundation for scientific research</i>	
	14:30 – 14:40	Institutional greetings and introduction	
	14:40 – 15:20	Organoids model human disease Hans Clevers, Basel, CH	

	15:20 – 16:00	Unconventional approaches to cancer therapy René Bernards, Amsterdam, NL	
	16:00 – 16:15	Patient-specific models of multicellular oncogenic competence in metastasis Arianna Baggolini, Bellinzona, CH	
	16:15 – 16:30	Q&A	
Polivalente room East Campus USI	14:30 – 17:30	UCLI – ICML JOINT SESSION LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE <i>In collaboration with Union for China Lymphoma Investigators - UCLI</i> Honorary co-chairs: Jun Ma, Harbin, CN, Jun Zhu, Beijing, CN, Franco Cavalli, Bellinzona, CH and Julie Vose, Omaha, NE, US Executive co-chairs: Yuqin Song, Beijing, CN, Junning Cao, Shanghai, CN, Emanuele Zucca, Bellinzona, CH and Laurence L. de Leval, Lausanne, CH	
	14:30 – 14:40	Welcome by the co-chairs	
	14:40 – 15:05	Introduction of Lymphoma Database of National Health Commission of the People's Republic of China Weiping Liu, Beijing, CN	073
	15:05 – 15:30	1998-2023 Twenty-five years of commitment to improving our understanding of lymphoma Emanuele Zucca, Bellinzona, CH	074
	15:30 – 15:55	Smart Start with Tislelizumab as the Front-line Treatment in Patients with High-risk Stage IIB and Advanced-stage Classical Hodgkin Lymphoma Zhiming Li, Guangzhou, CN	075
	15:55 – 16:10	Break	
	16:10 – 16:35	Role of checkpoint inhibitor in Germany Peter Borchmann, Cologne, DE	076
	16:35 – 17:00	New Drug Development in Lymphoma of China Is Going Global Keshu Zhou, Zhengzhou, CN	077

	17:00 – 17:25	New trends in lymphoma treatment in Western Countries Pier Luigi Zinzani, Bologna, IT	078
	17:25 – 17:30	Conclusions remarks by the co-chairs	
Room A, broadcast in room B, Marquee and Cinema Corso	15:15 – 15:30	Report of the 17-ICML Closed Workshop Bruce D. Cheson, Bethesda, MD, US	
Room A, broadcast in room B, Marquee and Cinema Corso	15:30 – 17:00	SESSION 13 - FOLLICULAR LYMPHOMA Chairs: Jonathan W. Friedberg, Rochester, NY, US and Eva Kimby, Stockholm, SE	
	15:30 – 15:45	A “Functional Cure” May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016 Mazyar Shadman, Seattle, WA, US	079
	15:45 – 16:00	SAKK 35/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy Emanuele Zucca, Bellinzona, CH	080
	16:00 – 16:15	Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study Pier Luigi Zinzani, Bologna, IT	081
	16:15 – 16:30	Odrone tamab in patients with relapsed/refractory follicular lymphoma (FL) grade 1–3a: Results from a prespecified analysis of the pivotal Phase II study ELM-2 Silvana Novelli, Barcelona, ES	082
	16:30 – 16:45	Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory follicular lymphoma and ≥2 prior therapies: updated analysis of a pivotal Phase II study Laurie H. Sehn, Vancouver, BC, CA	083

	16:45 – 17:00	Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high-risk follicular lymphoma, regardless of POD24 status David Belada, Hradec Králové, CZ	084
--	---------------	---	-----

Room A, broadcast in room B, Marquee and Cinema Corso	17:00 – 17:30	ESMO – ICML Special Lecture Does it matter how we name lymphomas? James O. Armitage, Omaha, NE, US	085
---	---------------	--	-----

Marquee	17:30 – 18:00	Farewell Coffee break	
----------------	---------------	------------------------------	--

Room A	18:00 – 19:00	THE BIG DEBATE MOVING TARGETS IN LYMPHOMA TREATMENT Chair: Emanuele Zucca, Bellinzona, CH <i>Satellite symposium organised by the Foundation for the Institute of Oncology Research (IOR)</i> Supported by sponsorship from Gilead Sciences Europe Ltd. Gilead has had no input into the agenda, speaker selection or content of the presentations used at this event.	
---------------	---------------	---	--

DEBATE 1.

Best therapy in aggressive mantle cell lymphoma: Time for frontline chemotherapy-free regimens?

YES - Michael L. Wang, Houston, TX, US

NO - Martin Dreyling, Munich, DE

DEBATE 2.

Towards a cure for relapsing/refractory diffuse large B cell lymphoma: Bispecific antibodies better than CAR-T cells?

YES - Laurie H. Sehn, Vancouver, BC, CA

NO - Gloria Iacoboni, Barcelona, ES

DEBATE 3.

Frontline treatment of advanced Hodgkin lymphoma: Should A+AVD replace PET-driven strategies?

YES - Stephen M. Ansell, Rochester, MN, US

NO - Peter Borchmann, Cologne, DE

SATURDAY, JUNE 17

Room A	08:45 – 10:15	SESSION 14 - NOVEL AGENTS Chairs: M. Lia Palomba, New York, NY, US and Anastasios Stathis, Bellinzona, CH	
---------------	---------------	---	--

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

08:45 – 09:00	High Complete Response Rate With TNB-486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Follicular Lymphoma: Interim Results from an Ongoing Phase 1 Study Ranjit Nair, Houston, TX, US	086
09:00 – 09:15	Phase 1b/2a study of AZD4573 (CDK9i) and acalabrutinib in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) Alexey Danilov, Duarte, CA, US	087
09:15 – 09:30	Phase 1 Study Of JNJ-67856633, A First-In-Human MALT1 Inhibitor, In Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) And Chronic Lymphocytic Leukemia (CLL) Mark Hertzberg, Randwick, NSW, AU	088
09:30 – 09:45	Enhancer of zeste homolog 2 (EZH2) inhibitor SHR2554 in relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL): updated outcomes from the first-in-human phase 1 study Yuqin Song, Beijing, CN	089
09:45 – 10:00	Open-label phase 1/2 study of CC-99282, a cereblon E3 ligase modulator (CELMoD) agent ± rituximab, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) Jean M. Michot, Villejuif, FR	090
10:00 – 10:15	Combining CD19-4-1BBL (R07227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell Non-Hodgkin Lymphoma Michael Dickinson, Melbourne, AU	091

Room B

08:45 – 10:15	SESSION 15 - IMMUNOTHERAPY FOR AGGRESSIVE LYMPHOMAS Chairs: Urban Novak, Bern, CH and Catherine Thieblemont, Paris, FR
---------------	--

08:45 – 09:00	Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma Martin Hutchings, Copenhagen, DK	092
09:00 – 09:15	Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal Phase II study ELM-2 Michelle Poon, Singapore, Singapore, SG	093
09:15 – 09:30	Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed/refractory large B-cell lymphoma: longer follow-up from the pivotal EPCORE NHL-1 trial Catherine Thieblemont, Paris, FR	094
09:30 – 09:45	Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study Michael Dickinson, Melbourne, AU	095
09:45 – 10:00	Bispecific anti-CD20/19 CAR-T - zamto-cabtagene autoleucel for relapsed/refractory DLBCL - Interim analysis results of DALY-II-USA Study Matthew Ulrickson, Gilbert, AZ, US	096
10:00 – 10:15	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Final Analysis of ALYCANTE, a Phase 2 LYSA Study Roch Houot, Rennes, FR	097

Room A

10:15 – 11:30	SESSION 16 - LATE BREAKING ABSTRACTS Chairs: Franco Cavalli, Bellinzona, CH and Martin Dreyling, Munich, DE	
10:15 – 10:30	Genome-wide association study of childhood Burkitt Lymphoma in East Africa identifies a novel germline susceptibility locus on chromosome 21 Sam M. Mbulaiteve, Rockville, MD, US	LBA1

10:30 – 10:45	Ibrutinib plus BR or R-CHOP in previously treated patients with Follicular or Marginal Zone Lymphoma: the phase 3 SELENE Study Loretta J. Nastoupil, Houston, TX, US	LBA2
10:45 – 11:00	Lisocabtagene maraleucel (liso-cel) in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design TRANSCEND NHL 001 study Michael L. Wang, Houston, TX, US	LBA3
11:00 – 11:15	TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL) Franck Morschhauser, Lille, FR	LBA4
11:15 – 11:30	BrECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin Lymphoma: efficacy results of the GHSG phase III HD21 trial Peter Borchmann, Cologne, DE	LBA5

Room B

10:15 – 11:05	“FOCUS ON...” SESSION Long term results of CLL trials Chairs: Barbara F. Eichhorst, Cologne, DE and John Seymour, Melbourne, AU	
10:15 – 10:25	5-Year (Y) Follow-up of a Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) as Initial Therapy for Younger CLL Patients (Pts) Inhye E. Ahn, Boston, MA, US	152
10:25 – 10:35	Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL Jacob D. Soumerai, Boston, MA, US	153
10:35 – 10:45	Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: Extended follow-up of the SEQUOIA study Mazyar Shadman, Seattle, WA, US	154

10:45 – 10:55	Fixed-duration ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study Paolo Ghia, Milan, IT	155
---------------	---	-----

10:55 – 11:05	MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) Arnon P. Kater, Amsterdam, NL	156
---------------	---	-----

Room A

11:30 – 11:50	17-ICML HIGHLIGHTS “Take Home Messages” Martin Dreyling, Munich, DE	
---------------	---	--

Room A

11:50 – 12:00	CLOSURE AND FAREWELL Franco Cavalli, Bellinzona, CH	
---------------	---	--

Room B

13:30 – 18:00	VI INTERNATIONAL WORKSHOP ON CANINE LYMPHOMA FOCUS ON CANINE T CELL LYMPHOMA <i>organized by the European Canine Lymphoma Network (open to all 17-ICML attendees)</i> Co-chairs: Luca Aresu, Turin, IT, Stefano Comazzi, Milan, IT, Fausto Guscelli, Zurich, CH and Laura Marconato, Bologna, IT	
---------------	---	--

THE EUROPEAN SCHOOL OF ONCOLOGY

is an independently funded **non profit organisation**
dedicated to **oncology education and training**



Extensive learning programmes to **reduce disparities**
and **promote multidisciplinary cancer care.**